Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Senti Biosciences, Inc. - Common Stock (NQ: SNTI )

2.270 -0.080 (-3.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 34,082
Open 2.360
Bid (Size) 2.240 (4)
Ask (Size) 2.300 (4)
Prev. Close 2.350
Today's Range 2.240 - 2.360
52wk Range 0.2111 - 2.930
Shares Outstanding 2,752,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Senti Bio Announces Reverse Stock Split
Shares expected to begin trading on split-adjusted basis on July 18, 2024 
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga

Performance

YTD
+243.42%
+243.42%
1 Month
+800.79%
+800.79%
3 Month
+656.67%
+656.67%
6 Month
+414.51%
+414.51%
1 Year
+160.92%
+160.92%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
SNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024
Via InvestorPlace
Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
Via MarketBeat
Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?
Via Benzinga
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
From Senti Biosciences, Inc.
Via GlobeNewswire
Why Is Beyond Air (XAIR) Stock Down 22% Today?
Via InvestorPlace
Why Is Faraday Future (FFIE) Stock Down 27% Today?
Via InvestorPlace
Why Is Senti Biosciences (SNTI) Stock Up 32% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
From Senti Biosciences, Inc.
Via GlobeNewswire
SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023
Via InvestorPlace
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.